Is Fragile X testing covered by Medicare?

Fragile X DNA testing is funded by Medicare under the following conditions:

  • Medicare item 73300 in the following circumstances: detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where:
  • (a) The patient exhibits intellectual disabilities, ataxia, neurodegeneration, or premature ovarian failure consistent with a FMR1 mutation; or
  • (b) The patient has a relative with the FMR1 mutation.
  • Medicare item 73305: Detection of genetic mutation of the FMR1 gene southern blot where the results in item 73300 are inconclusive.The name of the test is DNA Studies for Fragile X syndrome. 
  • From 1 November 2023: Medicare item 73451 – reproductive carrier testing for Fragile X, Cystic Fibrosis, Spinal Muscular Atrophy (Testing of a patient who is pregnant, or planning pregnancy, to identify carrier status for pathogenic or likely pathogenic variants in the following genes, for the purpose of determining reproductive risk of cystic fibrosis, spinal muscular atrophy or fragile X syndrome)

 

Please check with Medicare if you have any concerns.

Share:
Menu
Menu
Menu
Menu

End of Financial Year donation will make a difference

Your generous donation will help FXAA ensure people living with Fragile X are connected, included, understood and empowered. Specifically, your donation (no matter how big or small) will help us maintain and deliver support and connections to the Fragile X community: 1. Counselling support 2. FXAA Helpline - available 5 days per week 3. Webinar program 4. Peer connection and referrals 5. Advocacy work – for example, our Fragile X Care | Adults & Ageing study that we’re undertaking collaboratively with the Centre for Disability Studies is the first Australian study on the support needs, health & wellbeing of adults with Fragile X Syndrome as they age. All support is sincerely appreciated and helps us make a difference.

Donate
Fragile X Logo
Registered Charity Logo